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TO THE EDITOR
Protein tyrosine phosphatase N22
(PTPN22) is a key regulator of TCR
signalling in memory/effector T lym-
phocytes (Hasegawa et al., 2004). A
common, immunologically relevant
missense mutation R620W (c.1858C-
T) has consistently been associated with
several autoimmune diseases, for ex-
ample, diabetes and rheumatoid arthri-
tis (Begovich et al., 2004; Bottini et al.,
2004). Recently, Nistor et al. (2005)
reported lack of association of this
variant in a large study group of
psoriasis vulgaris families. These find-
ings confirmed two smaller previous
studies of (i) multiple autoimmune
families with psoriasis phenotype (Cris-
well et al., 2005) and (ii) 279 patients
with an early-onset form of chronic
plaques psoriasis and 455 patients with
psoriatic arthritis (PsA) (Hinks et al.,
2005). In a further study on rheumatoid
arthritis (Orozco et al., 2005b),
differences regarding carriers of
PTPN22*620W in clinical subgroups
of patients were observed. As rheuma-
toid arthritis and PsA share some
clinical similarities, we were interested
in whether PTPN22*620W might be a
relevant genetic factor in a subgroup of
PsA patients as well.
The patient sample with PsA as well
as the control group has been described
previously (Lascorz et al., 2005). In
brief, the 375 PsA patients of German
descent were recruited through four
different rheumatological centers in
Germany and the diagnosis was made
by a board-certified rheumatologist
according to the criteria of Moll
and Wright (1973). Average age of
onset for psoriasis vulgaris was
30.1713.0 years and diagnosis of PsA
was made X3 years before recruitment
in 78% of patients. The control cohort
consisted of 376 German (Caucasian)
healthy blood donors without psoriasis
vulgaris and no history or signs of
inflammatory joint disease at the time
of recruitment, when average age was
32710 years.
Written informed consent was ob-
tained from each patient and control
proband before enrolment. The investi-
gations were conducted according to
the Declaration of Helsinki Principles.
The medical ethical committee of the
universities of Munster and of Erlangen
had approved the described studies.
We genotyped R620W with a Taqman
assay on 7900HT Sequence Detection
System (Applied Biosystems, Foster
City, CA). Taqman genotypes could be
confirmed through direct sequencing in
a set of 24 randomly chosen probands.
Sequences of primers were F: 50-CCAG
CTTCCTCAACCACAATAAATG-30 and
R: 50-CAACTGCTCCAAGGATAGATG
ATGA-30, sequences of minor groove
binding probes were 50- TCAGGTGTC
CaTACAGG-30 and 50-TCAGGTGTCCg
TACAGG-30, labelled with VICTM and
6-FAMTM, respectively. Neither in cases
nor in controls significant deviation
from Hardy–Weinberg equilibrium was
found. To determine significant differ-
ences in genotype frequencies, statistics
was based on 22 table comparing
carriers homozygous for the wild-type
allele with the group of heterozygous
and homozygous risk allele carriers. To
address the multiple testing problem
and correct for the number of separate
tests performed, we derived adjusted
P-values using the permutation resam-
pling method from the MULTTEST
procedure with Fisher’s exact test for
two-group comparisons in the SAS
software package (version 9.1).
The minor allele nt 1858T of variant
R620W was not associated with sus-
ceptibility to PsA (Table 1), which is in
accordance with previous studies
(Hinks et al., 2005; Nistor et al.,
2005). Association of the PTPN22
variant has been detected in a variety
of autoimmune disorders, but it does
not seem to be of equal importance for
all complex diseases with a proposed
autoimmune pathogenesis. Thus, only a
minor or no relevance has been ob-
served inter alia for multiple sclerosis,
Crohn’s disease (van Oene et al., 2005)/
inflammatory bowel disease (Martin
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Table 1. Genotype frequencies of PTPN22*R620W (c.1858C-T) in PsA
patients and controls
PTPN22*620 genotype PsA patients1 (no. (%)) Healthy controls1 (no. (%))
C-C 281 (78.3) 299 (81.7)
C-T and T-T 78 (21.7) 67 (18.3)
w2 (1df) 1.326
P-value 0.250
1Owing to genotyping rates of 95.7% in PsA patients and 97.1% in controls, the total number of
genotypic data eligible for statistical analysis slightly differs from the total number of patients
included.
Individuals homozygous for the C allele were compared to individuals heterozygous and homo-
zygous for the mutant T allele.
Abbreviations: PsA, psoriatic arthritis; PSORS1, psoriasis susceptibility locus 1
et al., 2005), psoriasis vulgaris, and
ankylosing spondylitis (Orozco et al.,
2005a), an inflammatory disease of the
axial skeleton and peripheral joints
showing some clinical overlap with
PsA. Results for several diseases are
inconclusive: for example, juvenile
idiopathic arthritis (Hinks et al., 2005;
Seldin et al., 2005; Viken et al., 2005).
In coeliac disease, evidence for asso-
ciation to PTPN22*620W was identi-
fied only in a subgroup of patients with
an early-onset form (Zhernakova et al.,
2005). Therefore, we tested the hypo-
thesis that PTPN22*620W might be a
risk factor in a subgroup of patients
carrying the major genetic risk factor for
psoriatic skin disease at psoriasis sus-
ceptibility locus 1 (PSORS1) located at
HLA-C or within its neighboring region.
Owing to the extraordinary high link-
age disequilibrium within this region,
the disease-causing variant has not yet
been identified. We stratified for a risk
haplotype HCR*WWCC consisting of
two variants of the a-helix coiled-coil
rod homologue (CCHCR1 gene), as
previously described (Asumalahti
et al., 2003; Huffmeier et al., 2005c).
HCR*WWCC is in such strong linkage
disequilibrium with the HLA-Cw6 risk
allele at PSORS1 that it can be used as
an estimate of the risk allele (Asuma-
lahti et al., 2003). After stratification for
PSORS1 risk allele, we found no
evidence for association with
PTPN22*620W neither in carriers nor
in non-carriers of PSORS1 risk allele
(Table 2).
Next, we tested whether subgroups
with certain clinical characteristics of
PsA were associated with
PTPN22*620W (Table 2). The patient
group was stratified according to the
following criteria: manifestation as oli-
go- (p5 joints) or polyarthritis, spinal
involvement, erosive joint disease, and
sex. No significant differences were
observed for any of the features but for
male sex. Interestingly, the proportion
of male PsA patients in the
PTPN22*620W carriers was signifi-
cantly higher than in the subgroup
of female patients (Padj¼0.0065).
This sex-specific association with
PTPN22*620W was not biased by
differences in disease manifestation, as
male and female PsA patients did not
differ significantly with regard to oligo-
or polyarticular involvement of peri-
pheral joints, sacroiliitis/spondylitis, or
onset of disease (data not shown).
Interestingly, when using a similar
stratification strategy in rheumatoid
arthritis patients, a sex-specific trend
was observed, with males being more
prone to carry the risk allele (Orozco
et al., 2005b). In that study, though, this
effect was not significant after correc-
tion for multiple testing, whereas in a
further rheumatoid arthritis study group
association of R620W was not affected
by sex (van Oene et al., 2005). Inter-
estingly, when we stratified an earlier
described cohort of 375 single patients
with an early-onset form of psoriasis
vulgaris without signs of arthritis
(Huffmeier et al., 2005a), we did
not detect this sex-specific difference
(Hu¨ffmeier et al., 2005b). These
results might indicate a specificity
of the PTPN22*620W association
for joint manifestation in psoriasis.
Certainly, this sex-specific effects of
PTPN22*620W on arthritic disease
susceptibility require further indepen-
dent confirmation for PsA. However,
the results of the present study already
raise questions concerning possible
underlying mechanisms. Known effects
of estrogens on the enhancement of
T-cell responses (Maret et al., 2003)
might provide a hypothetical explana-
tion as to why in females the genetic
impact of PTPN22*620W as a reinfor-
cing factor of T-cell receptor signaling
might be less important for PsA mani-
festation than in males. A comparable
sex-specific effect has been reported for
a polymorphism of the cytosolic acid
phosphatase as a susceptibility factor
for female patients with diabetes melli-
tus type I (Bottini et al., 2002). To our
knowledge, it has not been investigated
yet if males are at higher risk in diseases
other than rheumatoid arthritis that
show association to PTPN22*620W
(eg diabetes, etc).
Table 2. Distribution of genotypes in PsA patients after stratification for genetic markers at PSORS1 and clinical
characteristics
Phenotype






















C-C 153 (80.5) 128 (75.7) 201 (77.6) 68 (82.9) 57 (79.2) 197 (78.5) 145 (75.5) 89 (83.2) 156 (72.6) 125 (86.8)
C-T+T-T 37 (19.5) 41 (24.3) 58 (22.4) 14 (17.1) 15 (20.8) 54 (21.5) 47 (24.5) 18 (16.8) 59 (27.4) 19 (13.2)
Praw-value 0.31 0.35 1.00 0.14 0.0016
Padj-value 0.79 0.83 1.00 0.46 0.0065
1Owing to 95.7% genotyping rate and partly incomplete clinical documentation, the total number of genotypic data eligible for statistical analysis in each
subgroup differed from the total number of patients included. PsA: psoriatic arthritis; PSORS1: psoriasis susceptibility locus 1;
PSORS1 risk allele was inferred from HCR*WWCC haplotype at CCHCR1. After stratification for each of the traits, Fisher’s exact test was used to determine
differences between CC versus CT and TT genotypes, Padj-values correspond to permutation adjusted P-values.
Significant values are indicated in bold.
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In summary, variant R620W of
PTPN22 does not seem to play a major
role in susceptibility to PsA in general,
but if sex-specific differences are repli-
cated, they suggests that it might be a
relevant susceptibility factor in male
patients.
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